Mechelen, Belgium; 1 February 2017 – Galapagos NV announces dosing of the first patient with cystic fibrosis Class III with novel CF corrector GLPG2222 as an add-on to Kalydeco® in a Phase 2a study. Galapagos further announced the opening of an Investigational New Drug file with the US Food & Drug Administration for GLPG2222, triggering a $10 million milestone payment.